Drug Target Review

MARCH 26, 2024

In my role as Chief Business Development Officer at Osivax, my main challenge is taking the deep scientific work of our research & development team and simplifying it for various audiences Could you share an example of a specific project or research that you have worked on and the impact it has had in your field?

Vaccine 110

Vaccine Virus Immune Response Science 110

PLOS: DNA Science

FEBRUARY 8, 2024

Borrowed from Bacteria Researchers are using the gene editing tool CRISPR to improve upon naturally-evolved human microbiomes, to build a better probiotic. The molecular tools of CRISPR were borrowed and developed from the natural immune response of bacteria to viruses – bacteriophages – that infect them.

Immune Response 98

Immune Response DNA Engineering Virus 98

Drug Target Review

APRIL 17, 2024

HLA are the critical molecules that our immune systems use to present peptides to T cells and facilitate recognition and killing in immune responses to pathogens. HLA-II presents peptides to CD4 T cells thought to be important for indirectly helping immune responses and facilitating antibody production.

Immune Response 105

Immune Response Laboratories DNA Virus 105

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. The interim analysis from the phase 1 trial has been published online at the preprint server, medRxiv.

Immune Response 40

Immune Response Vaccine Clinical Trials Virus 40

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . The researchers saw the participants produce neutralising antibodies, which they believe is needed to help build immunity to COVID-19. million.

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

Broad Institute

JULY 11, 2024

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus.

Treatment 72

Treatment Immune Response Virus Drugs 72

Drug Target Review

SEPTEMBER 11, 2023

The solution devised by the Stanford research team involves creating a biomolecule that combines an enzyme-based “scissors” called mucinase (a type of protein-cutting enzyme known as a protease) with a cancer cell -targeting nanobody (a fragment of an antibody).

Immune Response 116

Immune Response Research Engineering Virus 116

Drug Target Review

JUNE 1, 2023

La Jolla Institute for Immunology (LJI), US, scientists demonstrated how antibodies obtained from a clinical study participant attach to the SARS-CoV-2 spike protein and neutralise the virus. The vaccine prompts the body to produce the spike protein, which allows the immune system to develop antibodies against the real virus.

Virus 97

Virus Vaccine Immune Response Research 97

The Pharma Data

MARCH 23, 2022

Researchers at Johns Hopkins Children’s Center report evidence from lab experiments that a chemical derived from a compound found abundantly in broccoli and other cruciferous plants may offer a potentially new and potent weapon against the viruses that cause COVID-19 and the common cold. alone each year.

Virus 52

Virus Immune Response Research Treatment 52

DrugBank

JULY 18, 2024

For instance, the influenza virus is notorious for its ability to undergo antigenic drift, accumulating mutations in its surface proteins that can render existing vaccines less effective.  Adjuvants are substances added to vaccines to enhance the immune response.

Vaccine 80

Vaccine Immune Response Clinical Trials Disease 80

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. For media and investors only. Issued: London UK. About the Phase 2 study. and Honduras.

Immune Response 52

Immune Response Vaccine Trials Treatment 52

Broad Institute

JUNE 27, 2024

There are currently no treatments, but researchers from the Whitehead Institute for Biomedical Research and Broad Institute of MIT and Harvard have developed an approach that could one day be used to turn off the gene encoding this protein throughout the brain to treat or even prevent prion disease.

Disease 142

Disease Therapies Engineering Clinical Trials 142

Drug Target Review

OCTOBER 26, 2023

1 Adeno-associated virus (AAV) vectors are the leading platform for in vivo gene delivery for the treatment of various human diseases. 9 In addition, host immune responses further add to the complexity of developing cell-specific AAV capsids for clinical applications.

Engineering 105

Engineering Virus Therapies Immune Response 105

The Pharma Data

JULY 15, 2021

Antibody and T-cell immune responses strong and stable at eight months after immunization Demonstrated neutralizing antibody activity against the Delta variant (B.1.617.2) of Beth Israel Deaconess Medical Center suggest maturation of B-cell response without further boosting. 1.1.7), Beta (B.1.351), 1.351), Gamma (P.1),

Immune Response 52

Immune Response Vaccine Clinical Trials FDA 52

SCIENMAG: Medicine & Health

JULY 24, 2023

A new paper in Biology Methods & Protocols, published by Oxford University Press, shows it may be possible to design vaccines that will induce a stronger immune response to infecting pathogens, such as the virus causing COVID-19.

Vaccine 60

Vaccine Bioinformatics Immune Response Virus 60

The Pharma Data

AUGUST 15, 2021

Even as several safe and effective COVID-19 vaccines are being administered to people worldwide, scientists are still hard at work developing different vaccine strategies that could provide even stronger or longer-lasting immunity against SARS-CoV-2 and its variants.

Vaccine 52

Vaccine Virus Immune Response Clinical Trials 52

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. Affected individuals miss parts of the gene or the entire gene.

Therapies 69

Therapies Immune Response DNA Virus 69

Drugs.com

JUNE 26, 2024

WEDNESDAY, June 26, 2024 -- The COVID virus, or rather people's immune response to it, has changed and it might be prudent to wait a couple days after symptoms start before taking a COVID test, researchers report.“For For COVID, we found that if you o.

Immune Response 52

Immune Response Virus Research 52

NIH Director's Blog: Drug Development

JUNE 30, 2020

A major one is: just how well do those particular antibodies neutralize the virus to fight off the infection and help someone recover from COVID-19? Fortunately, most people get better—but should the typical antibody response take the credit? Not surprisingly, all volunteers had produced antibodies in response to the virus.

Immune Response 52

Immune Response Virus Vaccine Research 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes.

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

DECEMBER 7, 2020

In an early-stage clinical trial with 65 volunteers in the United States, an experimental vaccine triggered strong immune responses to a wide range of flu virus strains and subtypes. The immune responses lasted at least 18 months, according to the researchers at Mount Sinai Health System, in New York City.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

AUGUST 27, 2020

A new effort is under way to understand how the immune system responds to coronavirus. Scientists from 17 UK research centres are attempting to answer questions such as how long immunity lasts and why disease severity varies so much. from UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR).

Immune Response 52

Immune Response Virus Vaccine Disease 52

The Pharma Data

DECEMBER 31, 2020

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. Researchers from the U.S. The spots were surrounded by T cells — signs of an immune response. THURSDAY, Dec.

Immune Response 52

Immune Response Virus Doctors Research 52

The Pharma Data

DECEMBER 31, 2020

Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. The spike protein binds to the ACE2 receptor on human cells, which allows the virus to enter the cell. So, there are a lot of other things going on.

Research 52

Research Virus Immune Response Cell Biology 52

The Pharma Data

NOVEMBER 27, 2020

UK firm develops solution for identifying whether patients are actually infectious from a virus or not. Iceni Diagnostics has revealed it is developing a new technology that can disclose if patients are actually infectious with a live virus or not. Read on to for the full insight.

Virus 52

Virus Vaccine International Immune Response 52

The Pharma Data

JANUARY 31, 2021

Nasdaq: VIRI), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, announced today that it is entering a collaboration with Dr. Michael Camilleri of the Mayo Clinic to explore the role of antiviral therapy in managing Irritable Bowel Syndrome (IBS).

Immune Response 52

Immune Response Research Therapies Disease 52

Drug Target Review

JANUARY 15, 2024

Each T cell expresses a TCR specific for an HLA‑presented peptide signal, and when that signal is detected a T cell expressing the relevant TCR can launch a complex array of immune effector responses that can suppress or destroy tumours or virus-infected cells. Many potential candidate antigens are under consideration.

Engineering 110

Engineering DNA Virus Immune Response 110

Codon

FEBRUARY 13, 2024

Goodsell, RCSB Protein Data Bank and Scripps Research. Goodsell, RCSB Protein Data Bank and Scripps Research. 1 Yet even after more than two decades of research, media hype, and dozens of clinical trials and biotech start-ups that have come and gone, phage therapy has not scaled. Read it on our website here.

Therapies 117

Therapies DNA Virus Clinical Trials 117

The Pharma Data

MARCH 3, 2022

Senior Vice President and Head of Vaccine Research & Development at Pfizer Inc. “If If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials Trials 52

Vial

DECEMBER 11, 2023

Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. Despite advances in clinical research, there remain significant challenges as only 20% of HCV cases are diagnosed, and of these, only 15% receive treatment.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Target Review

JANUARY 3, 2024

Researchers from the Baylor College of Medicine have discovered that antibodies produced by llamas, called nanobodies, could be developed as a therapeutic agent to neutralise human norovirus. This is because this blocks the transmission chain, preventing the virus from spreading from cell to cell. Viruses in the GII.4 4 norovirus.

Virus 64

Virus Immune Response Vaccine Disease 64

Codon

SEPTEMBER 29, 2024

The lab created a plan with eight research institutions across three continents. Marketed as a gesture of scientific goodwill, it also gave the companies the benefit of further academic research into their models free of charge. Models of life became the dominant research paradigm in nearly every life-sciences field.

Engineering 132

Engineering Virus DNA Therapies 132

The Pharma Data

NOVEMBER 16, 2020

16, 2020 — Scientists are reporting early success with an experimental herpes vaccine that uses a genetically modified version of the virus. The gene edit prevents the virus from performing its normal evasive maneuver: hiding out in nervous system cells in order to elude the immune system. MONDAY, Nov.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

AUGUST 9, 2021

Research by Lancaster University scientists to create a COVID-19 vaccine which can be administered through the nose has taken a significant step forward. The pre-clinical animal trials of the intranasal vaccine showed a reduction in both the impact of the disease itself and transmission of the virus.

Vaccine 52

Vaccine Virus Immune Response Disease 52

The Pharma Data

NOVEMBER 23, 2021

The population’s immunity to SARS-CoV-2, achieved either through infection or vaccination, is crucial to overcome the COVID-19 pandemic. In their study, the researchers used a specially developed assay to analyze antibody levels against four other human coronaviruses in 825 serum samples taken before SARS-CoV-2 emerged.

Immune Response 52

Immune Response Vaccine Virus Hospitals 52

The Pharma Data

MARCH 8, 2022

SARS-CoV-2 viruses can hide from recognition by the immune system. However, the antiviral immune receptor RIG-I can be stimulated, which improves protection against lethal SARS-CoV-2 infections. Researchers led by Prof. Camouflage protects virus from immune system. SARS-CoV-2 belongs to the genus Betacoronavirus.

Clinical Pharmacology 52

Clinical Pharmacology Immune Response RNA Virus 52

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52